Skip to content

Behavioral Activation Therapy for Rural Veterans With Diabetes and Depression

Behavioral Activation Therapy for Rural Veterans With Diabetes and Depression

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01572389
Enrollment
225
Registered
2012-04-06
Start date
2012-11-01
Completion date
2016-09-30
Last updated
2017-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression, Diabetes Mellitus

Keywords

Diabetes Mellitus, Depression, Affective Symptoms, Self Care, Telemedicine, Psychotherapy

Brief summary

This clinical trial will compare the effectiveness of the Healthy Outcomes through Patient Empowerment (HOPE) intervention to enhanced usual care (EUC) for diabetes and depression at 6 and 12 month follow-up. The proposed study is a randomized controlled trial enrolling 242 largely rural Veterans with uncontrolled diabetes and clinically-significant depressive symptoms. Both groups will receive screening, education, and notification of clinical findings along with follow-up in usual primary care. HOPE participants will also receive behavioral coaching telephone sessions over a six month period. Patients in the control group will be screened, and providers will be notified of high risk patients' status and need for intervention. Both groups will receive only usual primary care during the subsequent 6 month maintenance period. Study measurements using self-report questionnaires will also be collected at baseline, 6 and 12 months follow-up. The investigators will also conduct chart reviews to evaluate usual care blood tests for diabetes control. Changes in measurements from baseline will be compared between groups. This intervention will reach Veterans in rural setting where community-based primary care is needed, especially care that blends treatment strategies for physical and emotional health.

Detailed description

Project Background: The co-occurrence of diabetes and depressive symptoms is highly prevalent and has dramatic consequences on the quality of life and health of affected patients. Due to the complex interrelation between these conditions, patients often experience both psychological and physiological difficulties. Furthermore, Veterans with diabetes and depressive symptoms in rural settings have limited access to care. Interventions that reach Veterans in rural / community-based primary care are needed, especially those that blend treatment strategies for physical and emotional health. Project Objectives: Specific (Primary) Aim (1): Compare the effectiveness of the Healthy Outcomes through Patient Empowerment (HOPE) intervention to enhanced usual care (EUC) at 6 and 12 month follow-up. Hypothesis 1a: After 6 months (active treatment phase), HOPE will produce greater improvements in diabetes control (measured by hemoglobin A1c levels) and depression (measured by PHQ-9 scores) than will EUC. Hypothesis 1b: At 12 months (6-month active phase plus 6-month maintenance phase), HOPE participants will continue to evidence significant greater improvements in HbA1c and PHQ-9 compared with EUC participants. Exploratory Specific Aim (2): To examine the role of moderators and mediators on intervention effectiveness Exploratory Aim 2a. To evaluate factors that mediate or moderate effectiveness at 6 and 12 months for all enrolled patients (regardless of intervention group assignment). Potential mediating and moderating variables include patient-level (clinical factors-diabetes distress and self-efficacy and sociodemographics) and facility-level factors (availability of medical and mental health services by clinical site). Exploratory Aim 2b. To evaluate factors that mediate or moderate effectiveness at 6 and 12 months for patients enrolled in the HOPE intervention arm. Intervention factors include adherence (e.g. session attendance), fidelity (ratings of coach effectiveness), and treatment implementation (e.g., goal setting quality and self-management behaviors) as well as any significant predictors obtained from Aim 1a. Exploratory Specific Aim (3): Evaluate the potential for embedding the HOPE intervention processes within a VA CBOC using the REAIM framework for evaluating effectiveness of behavioral interventions. Exploratory Aim 3a - Reach. Compare clinical and demographic characteristics of enrolled study participants with the characteristics of all potentially eligible patients at each CBOC. Exploratory Aim 3b - Adoption. Qualitatively elicit clinicians' perceptions of behavioral coaches, patients' use of action plans, and responses to coaches' recommendations in preparation for future implementation Project Methods: The proposed study is a randomized controlled trial enrolling 242 largely rural Veterans with uncontrolled diabetes and clinically-significant depressive symptoms. Both groups will receive screening, education, and notification of clinical findings along with follow-up in usual primary care. HOPE participants will also receive 6 behavioral coaching telephone sessions and 3 booster sessions over a six month period. Coaches will use a standardized, theory-based process for conducting the sessions with the aim of creating patient-centered and articulated goals and behavioral action plans. Participants' primary care providers will be notified about session discussions and the resultant goals and action plans. Both groups will receive only usual primary care during the subsequent 6 months maintenance period. Hemoglobin A1c and PHQ-9 measurements along with self-report questionnaires will also be collected at baseline, 6 and 12 months follow-up. Changes in measurements from baseline will be compared between groups. Analytic evaluations of intervention mediators/moderators and implementation will also be conducted at 6 and 12 months follow-up.

Interventions

BEHAVIORALHealthy Outcomes through Patient Empowerment (HOPE)

HOPE participants will receive 6 behavioral coaching telephone sessions and 3 booster sessions over a six month period followed by usual primary care during the subsequent 6 months maintenance period.

BEHAVIORALEnhanced Usual Care

All participants receive usual VA primary care plus a dedicated screening for diabetes control and clinically significant depressive symptoms. Patients and primary care providers are notified of these results and given recommendations for usual care.

Sponsors

VA Office of Research and Development
Lead SponsorFED

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Veterans with comorbid diabetes and depressive symptoms receiving primary care services at VA CBOCs throughout Southeast Texas * as well as MEDVAMC patients living \>20 miles from the hospital who face similar distance related treatment barriers Participants must have: * a diagnosis of diabetes mellitus * an average HbA1c level \>7.5% in the prior 6 months * clinically significant symptoms of depression * Verification of diabetes mellitus diagnoses will be based on data collected from the VA data warehouse. * To verify that participants meet the depression criteria, the investigators will use participant self-report of clinically significant depressive symptoms according to the PHQ-9, where a score of greater than/equal to 10 on the PHQ-9 will signify a clinically meaningful symptom burden.

Exclusion criteria

* The investigators will exclude potential participants only for clinical factors that would render a telephone-based behavioral activation intervention inappropriate. * Specific

Design outcomes

Primary

MeasureTime frameDescription
Change in Hemoglobin A1CHemoglobin A1C levels will be measured at baseline, 6-, and 12- months.Measures of Hemoglobin A1C will be taken to assess average blood glucose levels throughout the study as an indicator of diabetes control. Hemoglobin A1C is a blood test taken to assess average blood glucose levels in the body. Normal range of A1C level is below 5.7. Eligible participants had an A1C of 7.5 or higher. The higher the A1C the more a person's diabetes is uncontrolled.
Change in Patient Health Questionnaires-9 During InterventionPHQ-9 will be assessed at baseline, 6-, and 12- months.The Patient Health Questionnaires-9 assesses depressive symptoms during the course of the intervention. The PHQ-9 ranges in score from 0 - 27; where higher numbers represent increase levels of depression. Scores from 5 - 9 represent minimal symptoms of depression; 10 - 14 represent minor depression, dysthymia, or major depression - mild; 15 - 19 represent major depression, moderately severe; and scores of 20 and above is considered major depression, severe. Participants with that scored a 10 or above were eligible for the study.

Countries

United States

Participant flow

Pre-assignment details

There were a total of 225 participants enrolled into the study. Consent occurred at baseline and participants were eligible if they scored a 10 or greater on the PHQ-9 and an A1C of 7.5 or greater. If a participant didn't meet these criteria then they were not randomized into the study.

Participants by arm

ArmCount
Arm 1: HOPE
The Healthy Outcomes through Patient Empowerment (HOPE) intervention group is the intervention arm which will employ behavioral health coaching telephone sessions. Tele-coaching is a theoretically grounded, structured processes guided by intervention manuals. Healthy Outcomes through Patient Empowerment (HOPE): HOPE participants will receive 6 behavioral coaching telephone sessions and 3 booster sessions over a six month period followed by usual primary care during the subsequent 6 months maintenance period.
136
Arm 2: EUC
The Enhanced Usual Care (EUC) group will serve as a concurrent control group to compare to the intervention arm of the study. Participants are screened for diabetes self-management behaviors and control and for active depressive and anxiety symptoms. Primary care providers are alerted of the patients' status and given decision support to enhance care for these uncontrolled conditions. Enhanced Usual Care: All participants receive usual VA primary care plus a dedicated screening for diabetes control and clinically significant depressive symptoms. Patients and primary care providers are notified of these results and given recommendations for usual care.
89
Total225

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyDeath13
Overall StudyLost to Follow-up2514
Overall StudyOnly A1C or Assessment was Collected62
Overall StudyWithdrawal by Subject142

Baseline characteristics

CharacteristicArm 1: HOPEArm 2: EUCTotal
Age, Continuous62.6 years
STANDARD_DEVIATION 8.4
60.8 years
STANDARD_DEVIATION 8
61.9 years
STANDARD_DEVIATION 8.3
Race/Ethnicity, Customized
Race
Black
41 Participants16 Participants57 Participants
Race/Ethnicity, Customized
Race
Hispanic
12 Participants11 Participants23 Participants
Race/Ethnicity, Customized
Race
More than 1 race
8 Participants7 Participants15 Participants
Race/Ethnicity, Customized
Race
Other
2 Participants4 Participants6 Participants
Race/Ethnicity, Customized
Race
White
73 Participants51 Participants124 Participants
Sex: Female, Male
Female
15 Participants8 Participants23 Participants
Sex: Female, Male
Male
121 Participants81 Participants202 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
1 / 1363 / 89
other
Total, other adverse events
0 / 1360 / 89
serious
Total, serious adverse events
1 / 1360 / 89

Outcome results

Primary

Change in Hemoglobin A1C

Measures of Hemoglobin A1C will be taken to assess average blood glucose levels throughout the study as an indicator of diabetes control. Hemoglobin A1C is a blood test taken to assess average blood glucose levels in the body. Normal range of A1C level is below 5.7. Eligible participants had an A1C of 7.5 or higher. The higher the A1C the more a person's diabetes is uncontrolled.

Time frame: Hemoglobin A1C levels will be measured at baseline, 6-, and 12- months.

Population: The number analyzed at each timepoint decreased due to non-completion of the A1C blood draw by participants.

ArmMeasureGroupValue (MEAN)Dispersion
Arm 1: HOPEChange in Hemoglobin A1CBaseline9.2 percentage of glycated hemoglobinStandard Deviation 1.4
Arm 1: HOPEChange in Hemoglobin A1C6-Months9.1 percentage of glycated hemoglobinStandard Deviation 1.7
Arm 1: HOPEChange in Hemoglobin A1C12-Months8.7 percentage of glycated hemoglobinStandard Deviation 1.6
Arm 2: EUCChange in Hemoglobin A1CBaseline9.3 percentage of glycated hemoglobinStandard Deviation 1.5
Arm 2: EUCChange in Hemoglobin A1C6-Months8.7 percentage of glycated hemoglobinStandard Deviation 1.7
Arm 2: EUCChange in Hemoglobin A1C12-Months8.9 percentage of glycated hemoglobinStandard Deviation 2
Primary

Change in Patient Health Questionnaires-9 During Intervention

The Patient Health Questionnaires-9 assesses depressive symptoms during the course of the intervention. The PHQ-9 ranges in score from 0 - 27; where higher numbers represent increase levels of depression. Scores from 5 - 9 represent minimal symptoms of depression; 10 - 14 represent minor depression, dysthymia, or major depression - mild; 15 - 19 represent major depression, moderately severe; and scores of 20 and above is considered major depression, severe. Participants with that scored a 10 or above were eligible for the study.

Time frame: PHQ-9 will be assessed at baseline, 6-, and 12- months.

Population: The number analyzed at each timepoint decreased due to non-completion of the assessment by participants.

ArmMeasureGroupValue (MEAN)Dispersion
Arm 1: HOPEChange in Patient Health Questionnaires-9 During Interventionbaseline15.8 units on a scaleStandard Deviation 4.2
Arm 1: HOPEChange in Patient Health Questionnaires-9 During Intervention6 Months10.9 units on a scaleStandard Deviation 6.1
Arm 1: HOPEChange in Patient Health Questionnaires-9 During Intervention12 Months10.1 units on a scaleStandard Deviation 6.9
Arm 2: EUCChange in Patient Health Questionnaires-9 During Interventionbaseline16.2 units on a scaleStandard Deviation 4
Arm 2: EUCChange in Patient Health Questionnaires-9 During Intervention6 Months12.4 units on a scaleStandard Deviation 6
Arm 2: EUCChange in Patient Health Questionnaires-9 During Intervention12 Months12.6 units on a scaleStandard Deviation 6.5

Source: ClinicalTrials.gov · Data processed: Mar 20, 2026